Canada Approves Palovarotene treatment for FOP
On Jan 24, Ipsen announced the Canada approval of Sohonos (palovarotene). Indicated to reduce new bone formation in adults and children with FOP. Sohonos is approved for both chronic use, and for flare-ups. It is the first approval for Sohonos worldwide.
Canada Approves Palovarotene treatment for FOP Read More »